Sinned
2021-07-29
Like pls
J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":808933154,"tweetId":"808933154","gmtCreate":1627549580378,"gmtModify":1633763904061,"author":{"id":3578452158761953,"idStr":"3578452158761953","authorId":3578452158761953,"authorIdStr":"3578452158761953","name":"Sinned","avatar":"https://static.tigerbbs.com/d90fa3100a053e15ac93aedaaaaefe0c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls</p></body></html>","htmlText":"<html><head></head><body><p>Like pls</p></body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/808933154","repostId":1129345317,"repostType":4,"repost":{"id":"1129345317","kind":"news","pubTimestamp":1627549187,"share":"https://www.laohu8.com/m/news/1129345317?lang=&edition=full","pubTime":"2021-07-29 16:59","market":"us","language":"en","title":"J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant","url":"https://stock-news.laohu8.com/highlight/detail?id=1129345317","media":"The Wall Street Journal","summary":"Emergent BioSolutions received FDA approval to resume manufacturing after being shut down for contamination","content":"<p>Emergent BioSolutions Inc. plans to resume Covid-19 vaccine production at its Baltimore plant after getting the green light from the Food and Drug Administration, according to a statement from the company and an FDA letter reviewed by the Journal.</p>\n<p>“We are proud to be resuming production of bulk Covid-19 vaccine batches following additional reviews and collaboration with FDA and our manufacturing partners,” Emergent CEO Robert Kramer said in a statement late Wednesday. “We are grateful for the opportunity to help bring this global pandemic to an end.”</p>\n<p>The plant makes vaccines for Johnson & Johnson.</p>\n<p>While domestic demand for the Johnson & Johnson shot has dwindled in recent months, the Biden administration is seeking the shots to be exported to countries needing protection against Covid-19.</p>\n<p>The Baltimore plant had been shut down after FDA inspectors determined there was severe contamination at the plant.</p>\n<p>FDA officials didn’t immediately return calls for comment late Wednesday.</p>\n<p>In a letter from the FDA to Emergent on Wednesday viewed by the Journal, the federal agency said, “Based upon our current observations of the implemented corrective actions, FDA does not object to the resumption of manufacturing” at the Baltimore plant.</p>\n<p>One person familiar with the issue said the Emergent plant in Baltimore, once it is operating at full capacity, could make as many as 120 million doses a month. Those finished doses might not be available until this fall, however, the person said.</p>\n<p>J&J didn’t immediately respond to requests for comment.</p>\n<p>J&J still has up to 30 million doses that were made earlier at the Baltimore plant left to be potentially cleared for use. J&J’s vaccines are one-dose shots.</p>\n<p>That vaccine, along with other doses from AstraZeneca PLC, was made at the plant before the FDA action in April leading to the shutdown of the facility. The AstraZeneca vaccine is given as a two-shot regimen.</p>\n<p>The AstraZeneca vaccine doses that were produced at the facility still haven’t been cleared for use by the FDA.</p>\n<p>The FDA still plans a further, more comprehensive review of the plant after production is under way.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-29 16:59 GMT+8 <a href=https://www.wsj.com/articles/j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043?mod=hp_lista_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Emergent BioSolutions Inc. plans to resume Covid-19 vaccine production at its Baltimore plant after getting the green light from the Food and Drug Administration, according to a statement from the ...</p>\n\n<a href=\"https://www.wsj.com/articles/j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043?mod=hp_lista_pos3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.wsj.com/articles/j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043?mod=hp_lista_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129345317","content_text":"Emergent BioSolutions Inc. plans to resume Covid-19 vaccine production at its Baltimore plant after getting the green light from the Food and Drug Administration, according to a statement from the company and an FDA letter reviewed by the Journal.\n“We are proud to be resuming production of bulk Covid-19 vaccine batches following additional reviews and collaboration with FDA and our manufacturing partners,” Emergent CEO Robert Kramer said in a statement late Wednesday. “We are grateful for the opportunity to help bring this global pandemic to an end.”\nThe plant makes vaccines for Johnson & Johnson.\nWhile domestic demand for the Johnson & Johnson shot has dwindled in recent months, the Biden administration is seeking the shots to be exported to countries needing protection against Covid-19.\nThe Baltimore plant had been shut down after FDA inspectors determined there was severe contamination at the plant.\nFDA officials didn’t immediately return calls for comment late Wednesday.\nIn a letter from the FDA to Emergent on Wednesday viewed by the Journal, the federal agency said, “Based upon our current observations of the implemented corrective actions, FDA does not object to the resumption of manufacturing” at the Baltimore plant.\nOne person familiar with the issue said the Emergent plant in Baltimore, once it is operating at full capacity, could make as many as 120 million doses a month. Those finished doses might not be available until this fall, however, the person said.\nJ&J didn’t immediately respond to requests for comment.\nJ&J still has up to 30 million doses that were made earlier at the Baltimore plant left to be potentially cleared for use. J&J’s vaccines are one-dose shots.\nThat vaccine, along with other doses from AstraZeneca PLC, was made at the plant before the FDA action in April leading to the shutdown of the facility. The AstraZeneca vaccine is given as a two-shot regimen.\nThe AstraZeneca vaccine doses that were produced at the facility still haven’t been cleared for use by the FDA.\nThe FDA still plans a further, more comprehensive review of the plant after production is under way.","news_type":1},"isVote":1,"tweetType":1,"viewCount":115,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/808933154"}
精彩评论